Title page

1

2

3

5

7

11

Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive

- 4 breast cancer (PERSIST): A multicenter phase II trial
- 6 **Running Title:** Extended adjuvant therapy for breast cancer
- 8 Feilin Cao^{1#*}, Zhaosheng Ma^{1*}, Zenggui Wu^{1*}, Weizhu Wu², Ouchen Wang³, Binbin Cui^{1&}, Xiaotao Zhu^{4&},
- 9 Jing Hao⁵, Xiaochun Ji², Zhanwen Li⁶, Deyou Tao¹, Qingjing Feng⁷, Wei Lin⁸, Dongbo Shi⁹, Jingde Shu⁸,
- 10 Jichun Zhou¹⁰, Shifen Huang¹
- 12 ¹ Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical
- 13 University, Taizhou, China
- ² Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China
- 15 ³ Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou,
- 16 China
- ⁴ Department of Thyroid and Breast Surgery, Jinhua Municipal Central Hospital, Jinhua, China
- ⁵ Department of Thyroid and Breast Surgery, Yiwu Central Hospital, Jinhua, China
- 19 ⁶ Department of Breast Surgery, Ningbo Women & Children's Hospital, Ningbo, China
- ⁷ Department of Breast Surgery, Yiwu Maternity and Children Hospital, Jinhua, China
- 21 ⁸ Department of Surgical Oncology, Quzhou People's Hospital, Quzhou, China
- ⁹ Department of Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China
- 23 ¹⁰ Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
- 24 Hangzhou, China
- [#]Corresponding author:
- 27 Feilin Cao

25

- 28 Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University,
- No.150 Ximen Road, Taizhou 317099, Zhejiang Province, China.
- 30 Email: drcfl@126.com.
- * These authors contributed equally to this work and should be considered co-first authors.
- These authors contributed equally to this work and should be considered co-fourth authors.
- These authors contributed equally to this work and should be considered co-fifth authors.
- 35 [£] These authors contributed equally to this work and should be considered co-seventh authors.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Abstract Background Approximately one-third of patients with HER2-positive breast cancer experienced recurrence within 10 years after receiving 1 year of adjuvant trastuzumab. The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo. This study investigated the efficacy and safety of pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, after trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer. Methods This multicenter phase II trial was conducted at 23 centers in China. After enrollment, patients received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab). The primary endpoint was 2-year iDFS rate. **Results** Between January 2019 and February 2022, 141 eligible women were enrolled and treated. As of October 10, 2022, the median follow-up was 24 (interquartile range, 18.0-34.0) months. The 2-year iDFS rate was 94.59% (95% CI: 88.97-97.38) in all patients, 94.90% (95% CI: 86.97-98.06) in patients who completed 1-year treatment, 90.32% (95% CI: 72.93-96.77) in patients who completed only 6-month treatment, 96.74% (95% CI: 87.57-99.18) in the hormone receptor-positive subgroup, 92.77% (95% CI: 83.48-96.93) in the hormone receptor-negative subgroup, 96.88% (95% CI: 79.82-99.55) in the lymph node-negative subgroup, 93.85% (95% CI: 86.81-97.20) in the lymph node-positive subgroup, 97.30% (95% CI: 82.32-99.61) in patients with adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06-97.02) in patients with adjuvant trastuzumab. The most common adverse events were diarrhea (79.4%), fatigue (36.9%), lymphocyte count decreased (36.9%), nausea (33.3%), and hand-foot syndrome (33.3%). **Conclusion** Extended adjuvant pyrotinib administrated after trastuzumab-based adjuvant therapy showed promising efficacy in patients with high-risk HER2-positive breast cancer. The follow-up is ongoing to determine the long-term benefit. **Keywords:** Breast cancer; pyrotinib; human epidermal growth factor receptor 2; extended adjuvant therapy; invasive disease-free survival

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Background Worldwide, breast cancer is the most commonly diagnosed malignancy in women. Approximately 15-20% of breast cancer cases are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) (1, 2). Over the past 20 years, with the emergence of HER2-targeted agents, it has been proved that the addition of 1-year trastuzumab to adjuvant chemotherapy significantly reduces the recurrence rate and prolongs survival in patients with HER2-positive breast cancer (3-5). However, the phase III HERA study found that, despite receiving 1 year of adjuvant trastuzumab, 31% of patients with HER2-positive breast cancer experienced recurrence within 10 years (4). In addition, the phase III APHINITY study reported a 12% recurrence rate in HER2-positive breast cancer patients with node-positive disease after receiving 1 year of adjuvant trastuzumab, pertuzumab and chemotherapy with a median follow-up of 74 months (6). Consequently, novel treatment approaches are warranted to extend the time to recurrence. Currently, the efficacy of extended adjuvant therapy has only been investigated in the phase III ExteNET study. The results showed that 1 year of neratinib after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in women with HER2-positive breast cancer. However, the iDFS benefit did not translate into overall survival benefit in the intention-to-treat population after 8-year follow-up, except for patients with hormone receptor (HR)-positive disease (7-9). Pyrotinib is an oral irreversible pan-HER receptor tyrosine kinase inhibitor (TKI), targeting epidermal growth factor receptor, HER2, and HER4 (10-12). For patients with HER2-positive metastatic breast cancer, improved survival outcomes were shown in the pyrotinib group when compared with the control group in the phase III PHOEBE and PHILA studies (13, 14). Additionally, results from the phase III PHEDRA trial demonstrated clinical benefits of pyrotinib plus trastuzumab and docetaxel for patients with HER2-positive early or locally advanced breast cancer in the neoadjuvant setting (15). In the present PERSIST study, our objective was to assess the efficacy and safety of administering extended

adjuvant pyrotinib treatment following trastuzumab-based adjuvant therapy in patients with high-risk, HER2-

positive early or locally advanced breast cancer. This report presents the efficacy and safety results with a

median follow-up of 2 years, while longer follow-up is still ongoing.

Methods

90

91

Study design and participants

- 92 This multicenter, single-arm, investigator-initiated, phase II exploratory study was conducted at 23 sites in
- 93 China. The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang
- Province and all other participating centers, and the trial was performed in accordance with the 2013
- 95 Declaration of Helsinki. This trial was registered at ClinicalTrials.gov (NCT05880927). Written informed
- onsent was obtained from all patients before study enrollment.
- 97 Participants were eligible if they were women aged 18-75 years with high-risk, HER2-positive
- 98 (immunohistochemistry 3+, or 2+ with gene amplification by fluorescence in situ hybridization) early or
- 99 locally advanced invasive breast cancer; had previously completed 1 year of adjuvant therapy with either
- trastuzumab or trastuzumab plus pertuzumab within 6 months before enrollment; had an Eastern Cooperative
- Oncology Group performance status of 0 or 1; had known HR status; and had adequate bone marrow, hepatic,
- renal and cardiac functions.
- High-risk patients were defined as those meeting one of the following criteria: N stage ≥ 1 ; T stage ≥ 2 ; absence
- of pathological complete response (pCR) after neoadjuvant therapy; presence of pCR after neoadjuvant therapy
- but with tumor size ≥ 5 cm or N stage ≥ 2 ; tumor size < 2 cm but with high Ki-67 level or histologic grade 3.
- 106 Clinical and pathological stage was assessed according to the eighth edition of American Joint Committee on
- 107 Cancer tumor-node-metastasis staging system. The expression of Ki-67 was categorized as low (<20%) and
- high ($\geq 20\%$) based on the ratio of positive cells to all tumor cells in 10 high-power fields.
- The main exclusion criteria were bilateral breast cancer, inflammatory breast cancer, previous participation in
- other clinical trials involving anticancer therapy, allergies to the drug components in this protocol, history of
- immunodeficiency diseases, inability to swallow, and pregnancy or lactation.

112 **Procedure**

- Pyrotinib 400 mg was administrated orally once daily within 6 months of completing trastuzumab-based
- adjuvant therapy. Concurrent adjuvant endocrine therapy for HR-positive disease was recommended.
- 115 Treatment duration was 12 months unless intolerable adverse events, disease recurrence, death, or consent
- 116 withdrawal occurred.

Outcomes and assessment

- The primary endpoint was iDFS rate at 2 years. IDFS was defined as time from the initiation of pyrotinib
- treatment to invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local or regional
- invasive recurrence, distant recurrence, or death from any cause. The secondary endpoint was safety profile,
- graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version
- 122 4.0.

- Patients were followed every 3 months for the first 2 years. The follow-up assessments included physical
- examination, Eastern Cooperative Oncology Group performance status, complete blood count, blood chemistry

one safety assessment.

analysis, 12-lead electro-cardiogram, recording of adverse events, concomitant medications, and ultrasound. Computed tomography and bone scans may be conducted if clinically indicated.

Statistical analysis

Based on the previous ExteNET trial (16), the 2-year iDFS rate was assumed as 91% in the present study. To restrain the width of 2-sided 95% confidence interval (CI) to no more than 0.1, 126 patients were required. Considering a dropout rate of 10%, a total of 140 participants were recruited.

Continuous data were presented as median (range or interquartile range), while categorical data were presented as frequency (percentage). IDFS was estimated using the Kaplan-Meier method, and the corresponding 95% CI was estimated using the Brookmeyer-Crowley method. Efficacy analysis was performed in the full analysis set, which included all patients who received at least one dose of study drug. Safety analysis was performed in the safety set, defined as all patients who received at least one dose of the study drug and underwent at least

Results

138

139

Baseline characteristics

- Between January 2019 and February 2022, a total of 141 eligible women were enrolled in the study and
- received pyrotinib. All these patients were included in the full analysis set and safety set. The median age was
- 50 years (range, 25-72). Of the 141 patients, 107 (75.9%) patients had node-positive disease, and 64 (45.4%)
- had HR-positive disease. Detailed baseline characteristics are summarized in Table 1.
- In terms of treatment duration, 11 patients discontinued their treatment due to adverse events, while 38 patients
- had a treatment duration of less than or equal to 6 months due to the COVID-19 pandemic or personal reasons.
- 146 A total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib,
- respectively (Figure 1).
- 148 Efficacy
- 149 As of October 10, 2022, the median follow-up duration was 24 (interquartile range, 18.0-34.0) months. Of the
- 150 141 patients, seven patients experienced iDFS events, including one local recurrence, three brain metastases,
- two lung metastases, and one death due to distant metastasis. The 2-year iDFS rate was 94.59% (95% CI:
- 152 88.97-97.38; Figure 2).
- Subgroup analyses showed that the 2-year iDFS rate was 94.90% (95% CI: 86.97-98.06) in the 1-year
- treatment subgroup and 90.32% (95% CI: 72.93-96.77) in the 6-month treatment subgroup (Figure 3A).
- 155 Concerning HR status, the 2-year iDFS rate was 96.74% (95% CI: 87.57-99.18) in patients with HR-positive
- breast cancer and 92.77% (95% CI: 83.48-96.93) in patients with HR-negative breast cancer (Figure 3B). In
- terms of lymph node status, the 2-year iDFS rate was 96.88% (95% CI: 79.82-99.55) in patients with lymph
- node-negative breast cancer and 93.85% (95% CI: 86.81-97.20) in patients with lymph node-positive breast
- cancer (Figure 3C). Regarding trastuzumab-based adjuvant regimen, the 2-year iDFS rate was 97.30% (95%)
- 160 CI: 82.32-99.61) in patients who received adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06-
- 161 97.02) in patients who received adjuvant trastuzumab (Figure 3D).
- 162 Safety

- The most frequently reported treatment-emergent adverse event was diarrhea (112 [79.4%]), followed by
- fatigue (52 [36.9%]), lymphocyte count decreased (52 [36.9%]), nausea (47 [33.3%]), and hand-foot syndrome
- 165 (47 [33.3%]). Forty-three patients (30.5%) experienced grade 3 diarrhea, while no grade 4 or higher adverse
- events was reported (Table 2). Treatment discontinuation occurred in 11 (7.8%) patients, due to grade 3
- diarrhea (n=8), grade 3 hand-foot syndrome (n=1), and intolerance (n=2). In addition, 16 patients had dose
- reduction because of adverse events.

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

may last and affect the results in the extended adjuvant period.

Discussion To the best of our knowledge, this multicenter phase II study is the first prospective study to explore the efficacy and safety of extended adjuvant pyrotinib after trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive breast cancer. Furthermore, while the ExteNET study only included patients who received neoadjuvant or adjuvant trastuzumab, over one-third of the patients in our study had received dual anti-HER2 blockade with trastuzumab and pertuzumab, making it more clinically applicable to current clinical practice (17). In China, pertuzumab was approved for the treatment of HER2-positive breast cancer in the adjuvant setting in 2018, and has been covered by medical insurance since 2020. The PERSIST study started in 2019, thus the proportion of eligible patients who received trastuzumab and pertuzumab in our study was relatively high. In addition, we conducted subgroup analyses to explore the differences in the efficacy of extended adjuvant pyrotinib across different prior adjuvant regimens, including trastuzumab plus pertuzumab or trastuzumab alone, and different treatment durations. Currently, only neratinib has been approved by Food and Drug Administration in the extended adjuvant setting for patients with HER2-positive early or locally advanced breast cancer. In the 2023 National Comprehensive Cancer Network guidelines, it has been recommended for the treatment of high-risk, HR-positive, HER2positive breast cancer (18). In the ExteNET study, 1-year neratinib treatment after adjuvant trastuzumab significantly improved iDFS in patients with HER2-positive breast cancer, with a 2-year iDFS rate of 93.9% in the neratinib group and 91.6% in the placebo group (9, 16). In our study, the 2-year iDFS rate was 94.59%, comparable to that in the ExteNET study. In terms of subgroup analyses, the HR-positive group seemed to show a numerically higher 2-year iDFS rate than the HR-negative group (96.74% vs. 92.77 %). Consistently, similar results were observed in the ExteNET study. The underlying mechanism may involve cross-talk between HR and HER2 pathways (19, 20). Preclinical studies have shown that in estrogen receptor+/HER2+ cell lines, neratinib treatment also suppresses the activity of estrogen reporter (21). In the present study, adjuvant endocrine therapy was recommended for patients with HR-positive disease when treated with pyrotinib, which may generate synergistic effects (22, 23). Regarding duration of treatment, the results showed that the 2-year iDFS rate was numerically higher with 1year pyrotinib treatment (94.90%) versus 6-month pyrotinib treatment (90.32%). In the adjuvant setting, a phase III PHARE trial compared 1-year adjuvant trastuzumab with 6-month treatment, and the non-inferiority was not achieved for disease-free survival. Therefore, 1-year adjuvant trastuzumab remained the standard treatment (24). Further studies are warranted to find the optimal duration of extended adjuvant pyrotinib. Adjuvant treatment regimens before extended adjuvant treatment may also be associated with iDFS. In the present study, the 2-year iDFS rate was 93.48% and 97.30% in the trastuzumab subgroup and trastuzumab plus pertuzumab subgroup, respectively. The APHINITY study demonstrated a significantly improved iDFS with adjuvant trastuzumab plus pertuzumab than with adjuvant trastuzumab alone (25). Therefore, the iDFS benefits

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

None of the patients in the PERSIST study received trastuzumab emtansine (T-DM1), which is now a standard of care for HER2-positive patients with residual cancer after neoadjuvant therapy based on the phase III KATHERINE trial (26). Since T-DM1 was approved in China in 2020 and was not covered by medical insurance until 2023, it has not been widely used in clinical practice. Recently, a real-world study showed that patients with metastatic breast cancer could benefit from pyrotinib-based therapy after T-DM1 treatment (27). Therefore, patients with high-risk breast cancer may also benefit from extended adjuvant pyrotinib after being treated with T-DM1 in the adjuvant setting, which needs further investigation. Regarding adverse events, diarrhea was the major safety concern in the present study, leading to treatment discontinuation in eight patients. This adverse event as well as vomiting and nausea are TKI-related common adverse events. The underlying mechanisms of these adverse events are not clear yet, and the mainstream hypothesis is that the growth and healing of epithelial cells in gastrointestinal tract are inhibited by TKIs (28, 29). In the present study, 43 (30.5%) patients experienced grade 3 diarrhea, which were consistent with previous studies of pyrotinib (11, 30). Noteworthy, primary prophylaxis was not mandatory in this PERSIST trial. Currently, loperamide hydrochloride has been found to significantly alleviate symptoms of diarrhea and reduce diarrhea-related treatment discontinuation. It has been recommended for patients treated with pyrotinib (31). In the PANDORA trial of pyrotinib plus docetaxel, the incidence of diarrhea was significantly lower in the loperamide prophylaxis group (8.9%) compared with the non-prophylaxis group (38.2%) (32). In the CONTROL trial, all cohorts that received loperamide prophylaxis and the dose escalation cohort of neratinib exhibited lower grade 3 diarrhea rates and fewer instances of diarrhea-related treatment discontinuation compared with ExteNET (33). The above two studies indicated that pyrotinib-related diarrhea could be controlled with prophylaxis or dose modification. There are several limitations in the present study. Firstly, our study was a single-arm study without control group. Secondly, patients who received T-DM1 therapy in the adjuvant setting were not enrolled. Thirdly, 27.0% of patients did not complete 1-year extended adjuvant pyrotinib due to COVID-19 pandemic or personal reasons. Finally, the follow-up time was short. A phase III clinical trial (NCT03980054) of extended adjuvant pyrotinib in patients with high-risk HER2-positive breast cancer is ongoing, which will further demonstrate the efficacy of extended adjuvant TKI and bring new hope for patients with high-risk HER2-positive breast cancer. **Conclusions** Our study suggests the potential of extended adjuvant pyrotinib in patients with high-risk HER2-positive early

or locally advanced breast cancer after trastuzumab-based adjuvant therapy. The follow-up is ongoing to determine the long-term benefit of extended adjuvant pyrotinib.

Author contributions

237

- Huiqiang Huang: Conceptualization (Equal); Resources (Equal); Visualization (Equal); Zhaosheng Ma:
- Conceptualization (Equal); Investigation (Equal); Writing original draft (Equal); Zenggui Wu: Investigation
- 240 (Equal); Methodology (Equal); Writing original draft (Equal); Weizhu Wu: Formal analysis (Equal);
- 241 Methodology (Equal); Software (Equal); Writing original draft (Equal); Ouchen Wang: Methodology
- 242 (Equal); Resources (Equal); Writing review & editing (Equal); **Binbin Cui:** Investigation (Equal); Project
- administration (Equal); Software (Equal); Xiaotao Zhu: Investigation (Equal); Resources (Equal); Writing –
- original draft (Equal); Jing Hao: Investigation (Equal); Writing original draft (Equal); Writing review &
- editing (Equal); Xiaochun Ji: Conceptualization (Equal); Supervision (Equal); Zhanwen Li: Methodology
- 246 (Equal); Project administration (Equal); Resources (Equal); **Deyou Tao:** Software (Equal); Validation (Equal);
- Qingjing Feng: Methodology (Equal); Supervision (Equal); Validation (Equal); Writing original draft
- 248 (Equal); Wei Lin: Methodology (Equal); Supervision (Equal); Writing original draft (Equal); Writing –
- review & editing (Equal); **Dongbo Shi:** Supervision (Equal); Validation (Equal); Visualization (Equal);
- Writing original draft (Equal); Writing review & editing (Equal); **Jingde Shu:** Software (Equal); Writing –
- review & editing (Equal); **Jichun Zhou:** Methodology (Equal); Supervision (Equal); Validation (Equal);
- Writing review & editing (Equal); **Shifen Huang:** Resources (Equal); Writing review & editing (Equal)
- 253 Acknowledgements
- We thank all the patients who participated in this trial and their families, as well as the investigators and staff.
- We thank Yan Luo (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for data
- interpretation and Yunning Yang (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.)
- for medical writing assistance according to Good Publication Practice Guidelines.
- 258 Funding
- 259 None.
- 260 Conflict of interest statement
- The authors declare no conflict of interests.
- 262 Ethics approval and consent to participate
- The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang
- 264 Province and all other participating centers, and the trial was performed in accordance with the 2013
- Declaration of Helsinki. Written informed consent was obtained from all participants.
- 266 Clinical trial registration number
- This trial was registered at ClinicalTrials.gov (NCT05880927).
- 268 Data availability statement
- Data supporting the findings of this study are available from the corresponding author upon reasonable request.

References 272 273 1 Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA: a Cancer Journal For 274 Clinicians 64(1), 2014. PMID: Q1, DOI: 10.3322/caac.21208 2 Loibl S and Gianni L: Her2-positive breast cancer. Lancet (London, England) 275 276 389(10087): 2415-2429, 2017. PMID: O1, DOI: 10.1016/S0140-6736(16)32417-5 277 3 Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, Martino S, Rastogi 278 P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, 279 Zujewski JA and Wolmark N: Trastuzumab plus adjuvant chemotherapy for human 280 epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from nsabp b-31 and ncctg n9831. Journal of Clinical Oncology: Official 281 282 Journal of the American Society of Clinical Oncology 32(33): 3744-3752, 2014. PMID: 283 Q1, DOI: 10.1200/JCO.2014.55.5730 284 4 Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, 285 Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, 286 Levland-Jones B, Bell R, Dowsett M and Jackisch C: 11 years' follow-up of trastuzumab 287 after adjuvant chemotherapy in her2-positive early breast cancer: Final analysis of the 288 herceptin adjuvant (hera) trial. Lancet (London, England) 389(10075): 1195-1205, 2017. 289 PMID: Q1, DOI: 10.1016/S0140-6736(16)32616-2 290 5 Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred 291 DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, 292 Perez EA, Press MF, Spears PA, Vance GH, Viale G and Hayes DF: Recommendations 293 for human epidermal growth factor receptor 2 testing in breast cancer: American society 294 of clinical oncology/college of american pathologists clinical practice guideline update. 295 Journal of Clinical Oncology: Official Journal of the American Society of Clinical 296 Oncology 31(31): 3997-4013, 2013. PMID: Q1, DOI: 10.1200/JCO.2013.50.9984 297 6 Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, 298 Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu T-W, Pieńkowski T, Toi M, 299 Wilcken N, Andersson M, Im Y-H, Tseng LM, Lueck H-J, Colleoni M, Monturus E, 300 Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G and Thomssen C: Adjuvant 301 pertuzumab and trastuzumab in early her2-positive breast cancer in the aphinity trial: 6 302 years' follow-up. Journal of Clinical Oncology: Official Journal of the American Society 303 of Clinical Oncology 39(13): 1448-1457, 2021. PMID: Q1, DOI: 10.1200/JCO.20.01204 304 7 Holmes FA, Moy B, Delaloge S, Chia SKL, Eilertsen B, Mansi J, Iwata H, Gnant M, 305 Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, 306 Patt D, Gokmen E, Gore I, Smith JW, Loibl S, Masuda N, Tomašević Z, Petráková K, 307 DiPrimeo D, Wong A, Martin M and Chan A: Overall survival with neratinib after 308 trastuzumab-based adjuvant therapy in her2-positive breast cancer (extenet): A 309 randomised, double-blind, placebo-controlled, phase 3 trial. European Journal of Cancer 310 (Oxford, England: 1990) 184(48-59, 2023. PMID: O1, DOI: 10.1016/j.ejca.2023.02.002 311 8 Lüftner D, Tesch H, Schmidt M, Hartkopf AD, Streicher S, Resch A, Genovese L, Rosé 312 C, Valenti R and Harbeck N: Neratinib as extended adjuvant therapy in patients with 313 copositive early breast cancer: German health technology assessment-driven analyses 314 from the extenet study. European Journal of Cancer (Oxford, England: 1990) 150(268-315 277, 2021. PMID: O1, DOI: 10.1016/j.ejca.2021.03.045 316 9 Martin M, Holmes FA, Eilertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, 317 Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R,

318 Gokmen E, Bashford A, Ruiz Borrego M, Kim S-B, Jakobsen EH, Ciceniene A, Inoue K, 319 Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, 320 Yao B, Xu F, Auerbach A, Buyse M and Chan A: Neratinib after trastuzumab-based 321 adjuvant therapy in her2-positive breast cancer (extenet): 5-year analysis of a randomised, 322 double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 18(12): 1688-1700, 2017. PMID, DOI: 323 324 10 Blair HA: Pyrotinib: First global approval. Drugs 78(16): 1751-1755, 2018. PMID, 325 DOI: 10.1007/s40265-018-0997-0 326 11 Ma F, Ouyang O, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, Hu X, 327 Zou J, Zhu X and Xu B: Pyrotinib or lapatinib combined with capecitabine in her2-328 positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: 329 A randomized, phase ii study. Journal of Clinical Oncology: Official Journal of the 330 American Society of Clinical Oncology 37(29): 2610-2619, 2019. PMID: Q1, DOI: 331 10.1200/JCO.19.00108 332 12 Guan X, Ma F, Li Q, Chen S, Lan B, Fan Y, Wang J, Luo Y, Cai R, Zhang P, Li Q 333 and Xu B: Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus 334 capecitabine for patients with her2-positive metastatic breast cancer: A pooled analysis of 335 two phase i studies. Biomarker Research 11(1): 21, 2023. PMID: Q1, DOI: 336 10.1186/s40364-023-00453-0 337 13 Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang 338 X, Yin Y, Cheng Y, Li W, Gu Y, Chen Q, Liu J, Cheng J, Geng C, Qin S, Wang S, Lu J, 339 Shen K, Liu Q, Wang X, Wang H, Luo T, Yang J, Wu Y, Yu Z, Zhu X, Chen C and Zou 340 J: Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of her2-341 positive metastatic breast cancer (phoebe): A multicentre, open-label, randomised, 342 controlled, phase 3 trial. The Lancet Oncology 22(3): 351-360, 2021. PMID: Q1, DOI: 343 10.1016/S1470-2045(20)30702-6 344 14 Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, 345 Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie 346 J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X and Xu B: Pyrotinib versus 347 placebo in combination with trastuzumab and docetaxel as first line treatment in patients 348 with HER2 positive metastatic breast cancer (phila): Randomised, double blind, 349 multicentre, phase 3 trial. BMJ 383:e076065, 2023. PMID: Q1, DOI: 10.1136/bmj-2023-350 076065 351 15 Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang 352 S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X 353 and Zou J: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for her2-positive breast 354 cancer (phedra): A double-blind, randomized phase 3 trial. BMC Medicine 20(1): 498, 355 2022. PMID: Q1, DOI: 10.1186/s12916-022-02708-3 16 Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, 356 357 Gokmen E, von Minckwitz G, Eilertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, 358 Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, 359 Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B and Martin M: Neratinib after 360 trastuzumab-based adjuvant therapy in patients with her2-positive breast cancer (extenet): 361 A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet

Oncology 17(3): 367-377, 2016. PMID: Q1, DOI: 10.1016/S1470-2045(15)00551-3

- 363 17 Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn 364 HJ, Winer EP and Gnant M: Customizing local and systemic therapies for women with 365 early breast cancer: The st. Gallen international consensus guidelines for treatment of 366 early breast cancer 2021. Annals of Oncology: Official Journal of the European Society For Medical Oncology 32(10): 1216-1235, 2021. PMID: Q1, DOI: 367 368 10.1016/j.annonc.2021.06.023 369 18 Bevers TB, Niell BL, Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, 370 Conant EF, Eghtedari M, Flanagan MR, Hawley J, Helvie M, Hodgkiss L, Hoyt TL, 371 Ivanovich J, Jochelson MS, Kulkarni S, Lancaster RB, Mauer C, Maxwell J, Patel BK, 372 Pearlman M, Philpotts L, Plecha D, Plichta JK, Shakeri S, Smith ML, Streibert CL, 373 Strigel RM, Tumyan L, Winkler NS, Wolverton DE, Bergman MA, Kumar R and 374 Stehman K: Nccn guidelines® insights: Breast cancer screening and diagnosis, version 375 1.2023. Journal of the National Comprehensive Cancer Network: JNCCN 21(9): 900-376 909, 2023. PMID: Q1, DOI: 10.6004/jnccn.2023.0046 377 19 Nahta R and O'Regan RM: Therapeutic implications of estrogen receptor signaling in 378 her2-positive breast cancers. Breast Cancer Research and Treatment 135(1): 39-48, 2012. 379 PMID: Q2, DOI: 10.1007/s10549-012-2067-8 380 20 Pegram M, Jackisch C and Johnston SRD: Estrogen/her2 receptor crosstalk in breast 381 cancer: Combination therapies to improve outcomes for patients with hormone receptor-382 positive/her2-positive breast cancer. NPJ Breast Cancer 9(1): 45, 2023. PMID: Q1, DOI: 383 10.1038/s41523-023-00533-2 384 21 Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, 385 González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, 386 Bryce R, Auerbach A and Arteaga CL: Extended adjuvant therapy with neratinib plus 387 fulvestrant blocks er/her2 crosstalk and maintains complete responses of er+/her2+ breast 388 cancers: Implications to the extenet trial. Clinical Cancer Research: an Official Journal 389 of the American Association For Cancer Research 25(2): 771-783, 2019. PMID: Q1, DOI: 390 10.1158/1078-0432.CCR-18-1131 391 22 Hu Z-Y, Yan M, Xiong H, Ran L, Zhong J, Luo T, Sun T, Xie N, Liu L, Yang X, 392 Xiao H, Li J, Liu B and Ouyang Q: Pyrotinib in combination with letrozole for hormone 393 receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast 394 cancer (pleherm): A multicenter, single-arm, phase ii trial. BMC Medicine 21(1): 226, 395 2023. PMID: Q1, DOI: 10.1186/s12916-023-02943-2 396 23 Zhang J, Meng Y, Wang B, Wang L, Cao J, Tao Z, Li T, Yao W and Hu X: 397 Dalpiciclib combined with pyrotinib and letrozole in women with her2-positive, hormone 398 receptor-positive metastatic breast cancer (lordships): A phase ib study. Frontiers In 399 Oncology 12(775081, 2022. PMID: Q2, DOI: 10.3389/fonc.2022.775081 400 24 Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, Lortholary A, Espié 401 M, Fumoleau P, Serin D, Jacquin J-P, Jouannaud C, Rios M, Abadie-Lacourtoisie S, 402 Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, 403 Paget-Bailly S, Henriques J and Grouin JM: 6 months versus 12 months of adjuvant 404 trastuzumab in early breast cancer (phare): Final analysis of a multicentre, open-label, 405 phase 3 randomised trial. Lancet (London, England) 393(10191): 2591-2598, 2019. 406 PMID: O1, DOI: 10.1016/S0140-6736(19)30653-1
- 25 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G,
 Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines

409 J, Gelber RD, Piccart M and Baselga J: Adjuvant pertuzumab and trastuzumab in early 410 her2-positive breast cancer. The New England journal of medicine 377(2): 122-131, 2017. 411 PMID, DOI: 10.1056/NEJMoa1703643 412 26 von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark 413 N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-414 Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, 415 Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel 416 SM and Geyer CE: Trastuzumab emtansine for residual invasive her2-positive breast 417 cancer. The New England Journal of Medicine 380(7): 617-628, 2019. PMID: Q1, DOI: 418 10.1056/NEJMoa1814017 419 27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis 420 of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis: 421 A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI: 422 10.1093/oncolo/oyad228 423 28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase 424 inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. 425 Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI: 426 10.1038/s41392-023-01469-6 427 29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: 428 Diarrhea induced by small molecule tyrosine kinase inhibitors compared with 429 chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies 430 19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493 431 30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: 432 Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive 433 metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023. 434 PMID: Q1, DOI: 10.1038/s41392-023-01322-w 31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of 435 436 pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of 437 Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978 438 32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, 439 Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-440 positive metastatic breast cancer: The pandora phase ii trial. Nature Communications 441 14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y 442 33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, 443 Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, 444 Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, 445 Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with 446 her2-positive early-stage breast cancer: The control trial. Annals of oncology: official 447 journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID, 448 DOI: 449

Table 1. Baseline characteristics of patients in the full analysis set

451

All (n=141)
50 (25-72)
43 (30.5%)
83 (58.9%)
11 (7.8%)
2 (1.4%)
2 (1.4%)
34 (24.1%)
49 (34.8%)
58 (41.1%)
77 (54.6%)
64 (45.4%)
119 (84.4%)
22 (15.6%)
26 (17.7%)
92 (65.2%)
49 (34.8%)

⁴⁵² 453

ER, estrogen receptor; PR, progesterone receptor.
Tumors were assessed as being ER or PR positive with a threshold of 1%.


Table 2. Treatment-emergent adverse events occurring in at least 10% of the patients.


455

Events, n (%)	All (n=1	141)
	Any grade	Grade 3
Diarrhea	112 (79.4%)	43 (30.5%)
Fatigue	52 (36.9%)	0
Lymphocyte count decreased	52 (36.9%)	0
Nausea	47 (33.3%)	0
Hand-foot syndrome	47 (33.3%)	1 (0.7%)
Hyperuricemia	33 (23.4%)	0
White blood cell count decreased	26 (18.4%)	0
Dizziness	26 (18.4%)	0
Anemia	24 (17.0%)	0
Vomiting	22 (15.6%)	0
Headache	19 (13.5%)	0
Creatinine increased	17 (12.1%)	0
Neutrophil count decreased	16 (11.3%)	0


Figure legends


- 459 **Figure 1.** Study flowchart.
- Figure 2. Kaplan-Meier estimates of invasive disease-free survival in the full analysis set.
- Figure 3. Kaplan-Meier curves for invasive disease-free survival in (A) patients who received
- 6-month (n=31) and 1-year pyrotinib treatment (n=92), (B) patients with hormone receptor-
- positive breast cancer (n=64) and hormone receptor-negative breast cancer (n=77), (C) patients
- with lymph node-positive breast cancer (n=107) and patients with lymph node-negative breast
- cancer (n=34), (D) patients who received adjuvant therapy with trastuzumab (n=92) and
- trastuzumab plus pertuzumab (n=49).





A





C

